Introduction: Head drop is an unusual clinical manifestation of myositis or neuromuscular weakness, and typically requires extensive investigation to identify the underlying pathology. Case report data are limited on this topic. Case description: A 72-year-old man with a background of extractable nuclear antigen (ENA) negative mixed connective tissue disease, trigeminal neuralgia, interstitial nephritis and ischaemic heart disease presented with an isolated head drop. On further prompting, he confirmed mild shortness of breath on exertion. He had sclerodactyly but no features of mechanic's hands. Serum creatinine kinase was 1398 IU/L. Electromyography was myelopathic. Muscle biopsy taken from the neck was inconclusive. He had a strongly positive anti-nuclear antibody (ANA) test, and borderline myositis ENA panel result with borderline positive anti-EJ antibody. The myositis panel result prompted further investigation for underlying interstitial lung disease. Pulmonary function testing revealed a restrictive picture, with KCO of 82%. High resolution computed tomography showed areas of fineinterstitial fibrotic change inall lobes. He was treated with a reducing course of oral prednisolone and 15mg weekly oral methotrexate with an excellent clinical response, with resolution ofthe headdrop and normalisation of serum CKvalue. Repeatpulmonary function testing remains stable after 5 months. Discussion: This is an unusual presentation of presumed anti-synthetase syndrome. As methotrexate had already been prescribed before the underlying lung pathology was identified with resulting excellent clinical response and stable respiratory symptoms, a multi-disciplinary decision was made to continue with this choice of disease modifying agent. The decision to use methotrexate in the presence of interstitial fibrosis is always difficult, and requires close liaison between rheumatology and respiratorycolleagues. Key learning points: Positive anti-synthetase antibodies should prompt further investigation for underlying interstitial lung disease. Head drop can be a first symptom of autoimmune myositis and warrants further investigation.
Introduction: Head drop is an unusual clinical manifestation of myositis or neuromuscular weakness, and typically requires extensive investigation to identify the underlying pathology. Case report data are limited on this topic. Case description: A 72-year-old man with a background of extractable nuclear antigen (ENA) negative mixed connective tissue disease, trigeminal neuralgia, interstitial nephritis and ischaemic heart disease presented with an isolated head drop. On further prompting, he confirmed mild shortness of breath on exertion. He had sclerodactyly but no features of mechanic's hands. Serum creatinine kinase was 1398 IU/L. Electromyography was myelopathic. Muscle biopsy taken from the neck was inconclusive. He had a strongly positive anti-nuclear antibody (ANA) test, and borderline myositis ENA panel result with borderline positive anti-EJ antibody. The myositis panel result prompted further investigation for underlying interstitial lung disease. Pulmonary function testing revealed a restrictive picture, with KCO of 82%. High resolution computed tomography showed areas of fineinterstitial fibrotic change inall lobes. He was treated with a reducing course of oral prednisolone and 15mg weekly oral methotrexate with an excellent clinical response, with resolution ofthe headdrop and normalisation of serum CKvalue. Repeatpulmonary function testing remains stable after 5 months. Discussion: This is an unusual presentation of presumed anti-synthetase syndrome. As methotrexate had already been prescribed before the underlying lung pathology was identified with resulting excellent clinical response and stable respiratory symptoms, a multi-disciplinary decision was made to continue with this choice of disease modifying agent. The decision to use methotrexate in the presence of interstitial fibrosis is always difficult, and requires close liaison between rheumatology and respiratorycolleagues. Key learning points: Positive anti-synthetase antibodies should prompt further investigation for underlying interstitial lung disease. Head drop can be a first symptom of autoimmune myositis and warrants further investigation. Conflicts of interest: The authors have declared no conflicts of interest. Introduction: Paraneoplastic dermatomyositis is a well-recognised clinical entity, and should prompt investigation for an underlying malignancy. Immunosuppressive treatment canbe effectivein control of both skin and muscle disease. The effect of checkpoint inhibitors for control of solid tumours on autoimmune paraneoplastic phenomena is yet to be fully understood. Case description:A 49-year-old female with abackground of melanoma on the left thigh 2014 (Breslow thickness 1.9mm, treated with wide local excision only) presented with classical features of dermatomyositis; facial erythema, V-sign, Gottron's papules, muscle weakness and elevated creatine kinase (CK) at 711 IU/L. An MRI of the upper arms was consistent with myositis. Myositis ENA panel was negative. She was initially treated with high dose oral prednisolone and weekly methotrexate. At presentation, there was no clinical or radiographic evidence of recurrent melanoma, but unfortunately after 7 months she developed a lump in the left groin which proved to be metastatic melanoma(stage IV M1a). Shewastreatedwith3monthspalliative pembrolizumab,butthiswasdiscontinued due to lack of clinical response, when an interval CT scan showed increasing volume of disease (progressive left pelvic, retroperitoneal and left supra-clavicular fossa lymphadenopathy). Her skin disease remained painful despite 20mg PO prednisolone and 25mg of subcutaneous methotrexate weekly, so she was treated with intravenous immunoglobulin (IVIG) 2g/kg planned to be given over 5 days. On day 3, she was found to be pyrexial at 38.2 degrees celcius prior to commencement of the infusion. Treatment was delayed by 2 days. On day 6 she was again apyrexial and the IVIG treatment was completed with IV paracetamol and 100mg IVhydrocortisone given alongside. Following the IVIG, she has developed areas of painful localised ulceration over the dorsi of her feet, limbs and forehead. Her skin disease remains active with facial swelling and erythema, florid Gottron's papules and periungual erythema. The ulcerated areas are discrete from the areas of known metastasis, and are considered to be secondary to severe dermal inflammation which is being treated with betnovate ointment, with a plan to introducehydroxychloroquine ifthere is noclinical improvement. Discussion: The use of checkpoint inhibitors to treat solid tumours is increasing. The autoimmune side effects of this group are well documented, and pembrolizumab is known to trigger dermatitis as a treatment related adverse event. However, the implications for checkpoint inhibitor use in an existing paraneoplastic autoimmune phenomenon is not yet understood. Key learning points: Thorough investigation for underlying malignancy is paramount in new dermatomyositis. Patients treated with checkpoint inhibitorsshould be monitoredclosely for disease activity. Introduction: This is a complex case of a 50-year-old lady who presented with peripheral synovitis, fever and rash. She developed ulcerative skin lesions, proximalmuscle weakness and pulmonary fibrosis. Case description: A 50-year-old woman presented with a 6-week history of joint pain and swelling, an erythematous rash and fever. No preceding illness. She had fibromyalgia and chronic low back pain. She had several courses of prednisolone 20mg for presumed reactive arthritis with no benefit. She was a non-smoker, did not drink alcohol and was unemployed. She had florid symmetrical synovitis affecting MCPs, PIPs, wrists, ankles and knees. She had an erythematous rash across her face, chest and upper arms. She was pyrexic at night when her skin became inflamed. ESR-35 and CRP-13. RF, anti-CCP, ANA, ANCA, ACE and ASOT titre were negative. U&E was normal. LFTs were elevated with GGT-113, ALP-143, AST-432 and ALT-281. CK-33, LDH-367 and ferritin-2573. CXR, urine dip and liver screen were normal. USS abdomen, ECHO, CT CAP and PFTs were normal. Skin biopsy showed features of interface dermatitis. Extended myositis panel was negative. MRI of thighs showed active myositis. Muscle biopsy was insufficient. Tumour markers, mammogram, USS of breasts, OGD and colonoscopy were normal. The working diagnosis was dermatomyositis. She was treated with hydroxychloroquine and prednisolone 60mg with little benefit. She had three pulses of IV methylprednisolone with good benefit for joints. Azathioprine was not tolerated. Skin worsened and she was treated with 5 days IV immunoglobulins. She developed ulcerating skin lesions and swabs confirmed pseudomonas which was treated with ciprofloxacin and topical steroids. Dapsone caused haemolysis. She was switched to mycophenolate. Joints flared when prednisolone was reduced below 60mg and she was treated with rituximab. She developed proximal muscle weakness. Repeat MRI of thighs showed further progression of active myositis. Extended myositis panel confirmed Anti-MDA5 myositis. HRCT showed established pulmonary fibrosis. The myositis tertiary referral centre recommended IV cyclophosphamide. She responded well with improvement in joints and skin and prednisolone was weaned. Discussion: This was a refractory case of anti-MDA 5 myositis which failed to respond to multiple immunosuppressive treatments. The patient failed high dose oral steroids initially and therefore treatment was escalated to IV methylprednisolone. Her joint disease responded but unfortunately her skin deteriorated. We treated with IV immunoglobulins with no benefit. She was unable to tolerate azathioprine and was switched to mycophenolate as an alternative steroid sparing agent. Despite steroids, mycophenolate and immunoglobulins her disease progressed with worsening myositis, ulcerating skin lesions and pulmonary fibrosis. Rituximab is a well-recognised potential treatment option for patients with myositis resistant to conventional treatment. The extended myositis panel revealed anti-MDA5 myositis, which is associated with rapidly progressive interstitial lung disease and ulcerative skin lesions. These are case reports in Rheumatology in 2017 which describe successful treatment with rituximab for anti-MDA5 myositis. However in this particular case, our patient failed to respond to rituximab. Cyclophosphamide is reserved for severe cases of myositis with rapidly progressive lung disease. We took the opportunity to discuss this case with the tertiary myositis referral centre in Liverpool and they advised to proceed with cyclophosphamide withgood benefit. This was an interesting case of anti MDA 5 myositis. The initial presentation was not classical for an inflammatory myopathy with peripheral synovitis, fever and a rash. This patient's signs and symptom evolved with development of muscle weakness and pulmonary fibrosis. CK was POSTER PRESENTATIONS 26 September 2019 i17
